325 related articles for article (PubMed ID: 29563137)
1. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.
Song J; Shi J; Dong D; Fang M; Zhong W; Wang K; Wu N; Huang Y; Liu Z; Cheng Y; Gan Y; Zhou Y; Zhou P; Chen B; Liang C; Liu Z; Li W; Tian J
Clin Cancer Res; 2018 Aug; 24(15):3583-3592. PubMed ID: 29563137
[No Abstract] [Full Text] [Related]
2. A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Lu CF; Liao CY; Chao HS; Chiu HY; Wang TW; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
Cancer Imaging; 2023 Jan; 23(1):9. PubMed ID: 36670497
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
4. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
5. Value of interim
Shao D; Cheng Y; Yuan ZS; Jiang BY; Wang SX
Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
[TBL] [Abstract][Full Text] [Related]
6. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
Schuette W; Schirmacher P; Eberhardt WEE; Dietel M; Zirrgiebel U; Muehlenhoff L; Thomas M
BMC Cancer; 2018 Feb; 18(1):135. PubMed ID: 29402243
[TBL] [Abstract][Full Text] [Related]
7. Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.
Dong ZY; Zhai HR; Hou QY; Su J; Liu SY; Yan HH; Li YS; Chen ZY; Zhong WZ; Wu YL
Oncologist; 2017 Jan; 22(1):61-69. PubMed ID: 28126915
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
[TBL] [Abstract][Full Text] [Related]
9. Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.
Kuiper JL; Heideman DA; Würdinger T; Grünberg K; Groen HJ; Smit EF
Clin Lung Cancer; 2015 Jan; 16(1):60-6. PubMed ID: 25242669
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1.
Lu Y; Liu Y; Oeck S; Glazer PM
Mol Cancer Res; 2018 Oct; 16(10):1458-1469. PubMed ID: 29934325
[TBL] [Abstract][Full Text] [Related]
11. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive decision support for NSCLC treatment using PET/CT radiomics.
Mu W; Jiang L; Zhang J; Shi Y; Gray JE; Tunali I; Gao C; Sun Y; Tian J; Zhao X; Sun X; Gillies RJ; Schabath MB
Nat Commun; 2020 Oct; 11(1):5228. PubMed ID: 33067442
[TBL] [Abstract][Full Text] [Related]
13. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
Arriola E; García Gómez R; Diz P; Majem M; Martínez Aguillo M; Valdivia J; Paredes A; Sánchez-Torres JM; Peralta Muñoz S; Barneto I; Gutierrez V; Andrade Santiago JM; Aparisi F; Isla D; Ponce S; Vicente Baz D; Artal A; Amador M; Provencio M
BMC Cancer; 2018 Jan; 18(1):106. PubMed ID: 29382302
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
15. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
[TBL] [Abstract][Full Text] [Related]
16. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
Wu TH; Hsiue EH; Lee JH; Lin CC; Liao WY; Ho CC; Shih JY; Yu CJ; Yang JC
Clin Lung Cancer; 2018 May; 19(3):e361-e372. PubMed ID: 29477365
[TBL] [Abstract][Full Text] [Related]
17. Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.
Yang L; Yang S; Liu Y; Li J; Hu X; Wang Y; Zhang Y; Wang Y
Thorac Cancer; 2018 Jun; 9(6):693-698. PubMed ID: 29655198
[TBL] [Abstract][Full Text] [Related]
18. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
19. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
20. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
